Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Cell-derived H1N1 Vaccine in Elderly Japanese
NCT01069367Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Apr 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of adjuvanted cell-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine in influenza A/H1N1 (H1N1), sponsored by Novartis. Started Mar 2010; status: completed.
02
Drugs
adjuvanted cell-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
03
Conditions
influenza A/H1N1 (H1N1)
Beyond the preview
Go deeper on NCT01069367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01069367.